KaydedilenlerDerginizi ekleyin

Dergiler / Glokom Katarakt / 2019 / Cilt: 14 - Sayı: 2

Usage of Tissue Plasminogen Activator for Blood Clot in XEN Stent Lumen

XEN Stent Lümeninde Oluşan Kan Pıhtısı için Doku Plazminojen Aktivatörü Kullanımı

Ali OLGUN
Eyüp DÜZGÜN
Murat KARAPAPAK
Dilek Güven YAŞİN
Sayfa
98–100
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Intracameral tPA is a useful option in breaking down the blood clot obstructing the XEN stent lumen but it should not be forgotten that anterior chamber hemorrhage may come out if it is applied in the early postoperative period.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:XEN 45 stent (Allergan, Dublin, CA) is a new minimally invasive glaucoma surgery (MIGS) method using the identical outfl ow pathway as trabeculectomy, but less conjunctival scarring.
📊
Temel Bulgular & Veri:A 65-year-old female underwent XEN stent implantation surgery, due to uncontrolled intraocular pressure and visual fi eld deterioration in the right eye despite medical treatment.
💡
Sonuç & Katkı:Intracameral tPA is a useful option in breaking down the blood clot obstructing the XEN stent lumen but it should not be forgotten that anterior chamber hemorrhage may come out if it is applied in the early postoperative period.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

XEN 45 stent (Allergan, Dublin, CA) is a new minimally invasive glaucoma surgery (MIGS) method using the identical outfl ow pathway as trabeculectomy, but less conjunctival scarring. A 65-year-old female underwent XEN stent implantation surgery, due to uncontrolled intraocular pressure and visual fi eld deterioration in the right eye despite medical treatment. Postoperative gonioscopy examination revealed a blood clot occluding the stent orifi ce. Intracameral injection of tissue plasminogen activator (tPA) was performed to dissolve the blood clot and to open the lumen. However, hyphema fi lling 2/3 of anterior chamber was developed on the fi rst day following injection. During follow up, hyphema was rapidly reduced by diffusing to subconjunctival area via stent and completely disappeared on post-operative 10th day. Intracameral tPA is a useful option in breaking down the blood clot obstructing the XEN stent lumen but it should not be forgotten that anterior chamber hemorrhage may come out if it is applied in the early postoperative period.

Abstract

XEN 45 stent (Allergan, Dublin, CA), trabekülektomi ile aynı dışa akım yolunu kullanan, ancak konjonktivada daha az skara sebep olan yeni bir minimal invaziv glokom cerrahisidir (MIGS). Altmış beş yaşındakadın hastaya, medikal tedaviye rağmen sağ gözde kontrolsüz göz içi basıncı ve görme alanı kaybında ilerleme nedeniyle XEN stent implantasyonu uygulandı. Ameliyat sonrası gonyoskopi incelemesi sırasında stent orifi sini tıkayan bir kan pıhtısı saptandı. İntrakameral doku plazminojen aktivatörü (tPA) enjeksiyonu, kan pıhtılarını çözmek ve lümen tıkanıklığını gidermek için yapıldı. Bununla birlikte, enjeksiyon sonrası 1. günde ön kamaranın 2/3'ünü dolduran hifema gelişti. İzlem sırasında hifemanın stent yoluyla subkonjonktival alana yayılarak hızla azaldığı görüldü ve postoperatif 10. günde hifema tamamen kayboldu. İntrakameral tPA, XEN stent lümenini tıkayan kan pıhtılarını çözmede faydalı bir seçenek olmakla birlikte, erken postoperatif dönemde uygulandığı takdirde ön kamara kanamasına sebep olabileceği unutulmamalıdır.

🔖

Bu Makaleye Atıf Yap

OLGUN, A., DÜZGÜN, E., KARAPAPAK, M., YAŞİN, D. G. (2019). Usage of Tissue Plasminogen Activator for Blood Clot in XEN Stent Lumen. Glokom Katarakt, Cilt: 14 - Sayı: 2, 98–100. https://ajindex.com/articles/161808

Kaynakça (10)

  1. Lewis RA. Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract Surg.2014;40:1301-6
  2. Perez-Torregrosa VT, Olate-Perez A, Cerda-Ibanez M, et al. Combined phacoemulsifi cation and XEN 45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016;91:415-21
  3. Galal A, Bilgic A, Eltanamly R, et al. XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications. J Ophthalmol. 2017;2017:5457246
  4. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Effi cacy, safety, and risk factors for failure of standalone ab interno gelatin micro stent implantation versus standalone trabeculectomy. Ophthalmology. 2017;124:1579-88
  5. De Gregorio A, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2017;doi: 10.1007/s10792-017-0571-x
  6. Schmitz K, Greite JH, Bartenschlager EM. Tissue plasminogen activator fort he treatment of postoperative intraocular fi brinous membranes following cataracts surgery. Ger J Ophthalmol. 1995;4(2):75-9
  7. Pinto Ferreira N, Abegão Pinto L, Marques-Neves C. XEN gel stent internal ostium occlusion: Ab-interno revision. J Glaucoma 2017;26:e150-e152
  8. Zalta AH, Sweeney CP, Zalta AK, et al. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Arch Ophthalmol. 2002; 120:1487–93
  9. Lundy DC, Sidoti P, Winarko T, et al. Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Ophthalmology. 1996;103:274- 82 10. Erol N, Ozer A, Topbas Set al. Treatment of intracameral fi brinous membranes with tissue plasminogen activator. Ophthalmic Surg Lasers Imaging. 2003;34:451-6
  10. Wedrich A, Menapace R, Ries E, et al. Intracameral tissue plasminogen activator to treat severe fi brinous effusion after cataract surgery. J Cataract Refract Surg. 1997;23:873-7.